Endocr Pract. 2020 Jun 2;26(6):675-687. doi: 10.4158/EP-2019-0555. Epub 2020 Mar 11.
To analyze the effects of methimazole (MMI)-containing combination regimens on the thyroid status and relapse rates in patients with Graves hyperthyroidism (GH) using a network meta-analysis to provide guidance for clinical application. We conducted a literature review, which identified 21 trials for inclusion. The major outcomes were serum free triiodothyronine (FT3) and free thyroxine (FT4) concentrations. The secondary outcome was relapse rate. A network meta-analysis was used to compare multiple regimens to identify the most advantageous regimen. The types of combined drugs included anti-oxidant complexes, selenium, vitamin D3, cholestyramine, risedronate, iodine, potassium bromide, immunosuppressants, and β-adrenergic antagonists. Regarding the FT3 results, the rank probability of the best result showed that potassium bromide (0.897) and vitamin D3 (0.833) had relative advantages in reducing FT3 at the 1-month time point. According to the time trend analysis, compared with the control treatment, cholestyramine and iodine showed advantages in reducing FT3 during the early stage (0 to 3 months). The immunosuppressants showed advantages in reducing FT3 during the late stage (>9 months) but not the early stage. Regarding the FT4 results, potassium bromide had the highest -score (.965) at the 1-month time point. Iodine and cholestyramine had advantages in reducing FT4 during the early stage. The immunosuppressants had advantages during both the early and late stages. MMI combined with cholestyramine or iodine was shown to regulate serum FT3 and FT4 during the early stage of GH. MMI combined with immunosuppressants had a long-term advantage in FT3/FT4 regulation and reduced the relapse rate. = antithyroid drug; = confidence interval; = free triiodothyronine; = free thyroxine; = Graves hyperthyroidism; = methimazole; = odds ratio; = randomized controlled trial; = standard mean difference; = traditional Chinese medicine.
采用网状 Meta 分析评估含甲巯咪唑(MMI)的联合方案对格雷夫斯甲亢(GH)患者甲状腺功能及复发率的影响,为临床应用提供指导。我们进行了文献回顾,共纳入 21 项研究。主要结局指标为血清游离三碘甲状腺原氨酸(FT3)和游离甲状腺素(FT4)浓度。次要结局指标为复发率。采用网状 Meta 分析比较多种方案,以确定最有利的方案。联合用药的类型包括抗氧化复合物、硒、维生素 D3、考来烯胺、利塞膦酸钠、碘、溴化钾、免疫抑制剂和β-肾上腺素能拮抗剂。FT3 结果方面,最佳结果的秩概率显示,在 1 个月时,溴化钾(0.897)和维生素 D3(0.833)在降低 FT3 方面具有相对优势。时间趋势分析显示,与对照组相比,考来烯胺和碘在早期(0 至 3 个月)降低 FT3 方面具有优势。免疫抑制剂在晚期(>9 个月)而非早期降低 FT3 方面具有优势。FT4 结果方面,溴化钾在 1 个月时的得分最高(0.965)。碘和考来烯胺在早期降低 FT4 方面具有优势。免疫抑制剂在早期和晚期均具有优势。MMI 联合考来烯胺或碘在 GH 早期可调节血清 FT3 和 FT4。MMI 联合免疫抑制剂在 FT3/FT4 调节方面具有长期优势,并降低复发率。=抗甲状腺药物;=置信区间;=游离三碘甲状腺原氨酸;=游离甲状腺素;= Graves 甲亢;=甲巯咪唑;=优势比;=随机对照试验;=标准均数差;=中药。